See other companies on Welcome to the Jungle
Ordaos Bio
Machine-driven drug design company
- 21-100 employees
- Healthcare
- B2B
- Artificial Intelligence
- SaaS
- MedTech
- Chelsea, New York, NY
Jump to section
Company mission
To create bespoke mini-proteins to enable ground-breaking therapeutics.
Our take
Ordaos is a biotech company that designs mini-proteins to help access life-saving treatments. These mini-proteins ultimately enable targeted therapies to reduce patient suffering by bettering their health, ideally extending their life; a potential revelation for the drug-discovery industry.
Ordaos has unique access to its own Design Engine that uses reinforcement learning to turn human-targeted product criteria into their manufactured mini-proteins, which are more therapeutically effective, cheaper and easier to develop, and less likely to have adverse effects on patients. Branded ‘Ordaos miniPRO’, these proteins deliver the performance of antibodies but are easier to manage and manipulate, hence are available to use on a wide number of bespoke clients with specific targets.
The industry’s trust in Ordaos’ offerings is marked by recent investment that will go towards maximizing drug candidate delivery speed, novelty and the probability of clinical success.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Competitive healthcare coverage through Blue Cross Blue Shield, dental and vision through Guardian Healthcare.
- 401k (traditional and Roth offered) with 100% match up to first 4% of pay.
- 10 days paid vacation and 5 sick days per year, in addition to 12 company paid holidays or floating holidays.
- Annual budget of $4000 per employee for continuing education.
- Free annual corporate membership to Citibike, Monthly commuter benefits up to $130, Free teletherapy sessions through Talkspace, "Compassionate Leave" policy allowing for 4 weeks of leave for any reason (grief, extended illness, abortion care, etc).
Company values
- Curiosity
- Openness
- Agility
- Innovation
- Boldness
Funding (last 2 of 3 rounds)
Sep 2024
$3.2m
LATE VC
Aug 2022
$5m
SEED
Total funding: $19.2m
Leadership
David Longo
(CEO)Previously founded Six Dots Sound, The Vocal Company, serving here as Chief Product Manager, and co-founded PDL. Experience as a Social Network Analysis Researcher for Rochester Institute of Technology and an Engineering Specialist for Solutionz.
Ulo Palm
(Board of Directors)Served as Chief Medical Officer for Ordaos until 2021 and current serves in this position for Vaxxinity. Spent 10 years at Schering Plough, 6 years at Novartis, 6 years at Forest Laboratories, one year at Actavis plc, 7 years at TransCelebrate BioPharma and 5 years at Allergan.
Ziwei Liang
(Senior Vice President)Previously served as Director of Research Development at Ordaos until May 2022. Previously worked as a Senior Scientist for GSK and an Immuno-Oncology Scientist for the Tri-Institutional Therapeutics Discovery Institute.